ODACTRA

Product approval information for use in adults 18 through 65 years of age as immunotherapy for house dust mite- (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust m

Related Articles

Welcome

QR Code to download the 360 Force for Health Academy App
LEARN It! Reality Health Games